Novo Nordisk & CagriSema: Obesity Drug Potential
- Novo Nordisk is pushing to unlock the "maximum potential weight loss" from its experimental drug, CagriSema.
- The average weight loss among patients was 22.7%, raising concerns that CagriSema might not effectively compete with Eli Lilly's blockbuster drug, Zepbound.
- Lange added that detailed results presented at the American Diabetes Association conference indicated CagriSema offered greater weight loss than Novo Nordisk's existing product, Wegovy, with a comparable side...
Novo Nordisk is aggressively pursuing the maximum potential of CagriSema, its experimental obesity drug, following initial trial results that disappointed investors. This proactive move aims to secure CagriSema’s role in the competitive obesity treatment market. Data presented at the American Diabetes Association conference revealed that CagriSema outperformed Wegovy in weight loss with a similar side effect profile, helping to ease investor concerns. Though, the company faces tough competition with Eli Lilly’s Zepbound adn market share loss. News Directory 3 provides comprehensive updates on these developments. with ongoing trials and strategic adjustments, Novo Nordisk is working to refine CagriSema’s dosage and duration. Discover what’s next for the company and its impact on addressing obesity.
Novo Nordisk Aims for Max Weight Loss Potential with CagriSema
Updated June 22, 2025
Novo Nordisk is pushing to unlock the “maximum potential weight loss” from its experimental drug, CagriSema. This effort aims to reassure investors who were disappointed by earlier trial results. The Danish company saw roughly €90 billion in market value evaporate in December when CagriSema missed its initial target of 25% average weight loss; only 40% of participants achieved that goal.
The average weight loss among patients was 22.7%, raising concerns that CagriSema might not effectively compete with Eli Lilly’s blockbuster drug, Zepbound. Martin Lange, executive vice president at Novo Nordisk, stated that the company has extended one CagriSema trial and initiated another, longer one to assess the drug’s effects beyond 68 weeks. The focus remains on CagriSema’s potential for meaningful weight loss.
Lange added that detailed results presented at the American Diabetes Association conference indicated CagriSema offered greater weight loss than Novo Nordisk’s existing product, Wegovy, with a comparable side effect profile. The company hopes this data will alleviate investor concerns about CagriSema’s role in the obesity treatment market.
The data also suggests a positive impact on patients’ cardiovascular health,which Novo Nordisk is further investigating in a separate trial. disappointing CagriSema data contributed to a more than 50% drop in Novo Nordisk’s share price over the past year. The company also faces concerns about losing market share to Eli Lilly.
Last month, Novo Nordisk’s board ousted chief executive Lars Fruergaard Jørgensen. Analysts had previously criticized the company for setting a 25% weight loss target for the CagriSema trial and for not clearly communicating that participants were not on a fixed dose.
Lange noted that new data indicates that individuals who adjusted their dosage often experienced greater weight loss. He added, “Their desire for weight loss is not always a very, very fast and dramatic weight loss. That can be unhelpful.”
Novo Nordisk also recently announced results from two studies of amycretin,another obesity drug in earlier trial stages. an injectable version of amycretin resulted in an average weight loss of 24%, surpassing current market offerings. A pill version led to an average body weight loss of over 13%, with the company suggesting potential for higher results with longer-term use.
What’s next
Novo Nordisk will continue to analyze data from ongoing trials to determine the optimal dosage and duration for CagriSema, aiming to maximize its effectiveness and market potential in the competitive obesity treatment landscape.